{
    "clinical_study": {
        "@rank": "35213", 
        "arm_group": [
            {
                "arm_group_label": "DRM02", 
                "arm_group_type": "Experimental", 
                "description": "DRM02 Topical Gel, 0.25%"
            }, 
            {
                "arm_group_label": "Vehicle", 
                "arm_group_type": "Placebo Comparator", 
                "description": "DRM02 Topical Gel, Vehicle"
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to determine whether DRM02 is safe and effective in the\n      treatment of atopic dermatitis when applied twice daily for 6 weeks."
        }, 
        "brief_title": "A Safety and Efficacy of DRM02 in Subjects With Atopic Dermatitis", 
        "completion_date": {
            "#text": "March 2014", 
            "@type": "Actual"
        }, 
        "condition": "Atopic Dermatitis", 
        "condition_browse": {
            "mesh_term": [
                "Dermatitis", 
                "Dermatitis, Atopic"
            ]
        }, 
        "detailed_description": {
            "textblock": "This is a double-blind, randomized, within-subject control, study enrolling 20 subjects with\n      atopic dermatitis and designed to assess the safety, tolerability, and preliminary efficacy\n      of DRM02.\n\n      Safety will be assessed during the study, through adverse events, local skin responses,\n      urinalysis, serum chemistry and hematology laboratory testing, physical examination and\n      vital signs.\n\n      Preliminary efficacy will be assessed through the Physician's Lesion Assessment (PLA) and\n      the Eczema Area and Severity Index (EASI) from only the two lesions identified at the\n      baseline visit."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male or female 18 to 70 years of age.\n\n          -  Clinical diagnosis of stable atopic dermatitis (AD) and with two lesions of similar\n             size and have an identical score of at least 5 but no more than 9 on the sum of the\n             individual components of the Eczema Area and Severity Index (EASI) at the Target\n             Lesion scale.\n\n          -  Male or non-pregnant, non-lactating females.\n\n          -  Signed informed consent.\n\n        Exclusion Criteria:\n\n          -  Subjects who have unstable atopic dermatitis (AD).\n\n          -  Significant infection at the target lesion site.\n\n          -  Prior or concomitant use of systemic therapies for AD within the past 4 weeks.  -\n             Prior or concomitant use of topical treatments for AD, to within 10 cm of the target\n             lesion within the past 4 weeks.\n\n          -  Prior or concomitant use of oral retinoids for AD within the last 6 months.\n\n          -  Use of biologics for AD within the past 3 months, or 5 half-lives (whichever is\n             longer).\n\n          -  Subjects who have poor skin condition within 5 cm of the target lesion.\n\n          -  Subjects who are current drug or alcohol abusers; have a history of immunodeficiency\n             disease; or are a poor medical risk because of other systemic diseases or active\n             uncontrolled infections.\n\n          -  Subjects with an unstable medical condition or a medical condition not adequately\n             controlled with standard medical therapy.\n\n          -  Subjects who are actively participating in an experimental therapy study or who have\n             received experimental therapy within 30 days.\n\n          -  Subjects who have a clinically significant laboratory value at screening."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "21", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "November 15, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01993420", 
            "org_study_id": "DRM02-ADM02"
        }, 
        "intervention": [
            {
                "arm_group_label": "DRM02", 
                "intervention_name": "DRM02", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Vehicle", 
                "intervention_name": "Vehicle", 
                "intervention_type": "Other"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 14, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Drummondville", 
                        "country": "Canada", 
                        "state": "Quebec", 
                        "zip": "J2B5L4"
                    }, 
                    "name": "Clinique M\u00e9dicale Dr Isabelle Delorme"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Montreal", 
                        "country": "Canada", 
                        "state": "Quebec", 
                        "zip": "H2K 4L5"
                    }, 
                    "name": "Innovaderm Research, Inc"
                }
            }
        ], 
        "location_countries": {
            "country": "Canada"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized, Double-blind, Vehicle Controlled Study of the Safety and Efficacy of Topical DRM02 in Subjects With Atopic Dermatitis", 
        "other_outcome": [
            {
                "measure": "Physician's Lesion Assessment dichotomized into \"success\" and \"failure\"", 
                "safety_issue": "No", 
                "time_frame": "Week 6"
            }, 
            {
                "measure": "Severity of Target Lesion EASI scores", 
                "safety_issue": "No", 
                "time_frame": "Week 6"
            }
        ], 
        "overall_official": {
            "affiliation": "Dermira, Inc.", 
            "last_name": "Beth Zib", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Canada: Health Canada", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "February 2014", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Change in Physician's Lesion Assessment", 
            "safety_issue": "No", 
            "time_frame": "Week 6"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01993420"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Physician's Lesion Assessment analyzed for treatment effect", 
            "safety_issue": "No", 
            "time_frame": "From baseline to weeks 1, 2, 3, 4 and 6"
        }, 
        "source": "Dermira, Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Dermira, Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}